Key Points
- Insider sale: Director Christopher Sarchi sold 6,500 shares on April 2 at an average of $8.01 under a pre-arranged Rule 10b5-1 plan, reducing his stake by 4.11% to 151,588 shares valued at about $1.21 million.
- Stock snapshot: REPL traded around $8.54 with a 1‑year range of $2.68–$13.24 and a market cap of about $705.15 million, with 50- and 200-day moving averages near $7.61 and $7.89 respectively.
- Outlook and analysts: Replimune is a clinical-stage biotech (lead candidate RP1) that recently beat quarterly EPS expectations (‑$0.77 vs. ‑$0.85), and holds a MarketBeat consensus rating of "Hold" with a $10 price target (six Buys, two Holds, two Sells).
Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) insider Christopher Sarchi sold 6,500 shares of the business's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total transaction of $52,065.00. Following the transaction, the insider owned 151,588 shares in the company, valued at $1,214,219.88. This represents a 4.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Replimune Group Trading Up 1.5%
Shares of NASDAQ REPL opened at $8.54 on Tuesday. Replimune Group, Inc. has a 1 year low of $2.68 and a 1 year high of $13.24. The stock has a market cap of $705.15 million, a P/E ratio of -2.48 and a beta of 0.74. The firm has a 50-day moving average of $7.61 and a 200 day moving average of $7.89. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60.
Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.08. As a group, sell-side analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.
Hedge Funds Weigh In On Replimune Group
A number of hedge funds have recently modified their holdings of the company. Invesco Ltd. boosted its position in shares of Replimune Group by 297.3% in the fourth quarter. Invesco Ltd. now owns 613,015 shares of the company's stock worth $5,959,000 after purchasing an additional 458,714 shares during the period. XTX Topco Ltd bought a new position in shares of Replimune Group in the fourth quarter worth approximately $322,000. Virtus Investment Advisers LLC boosted its position in shares of Replimune Group by 127.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 26,133 shares of the company's stock worth $254,000 after acquiring an additional 14,622 shares during the last quarter. SummitTX Capital L.P. bought a new position in shares of Replimune Group during the fourth quarter worth $1,058,000. Finally, Susquehanna Portfolio Strategies LLC bought a new position in shares of Replimune Group during the fourth quarter worth $650,000. 92.53% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on REPL. Wedbush boosted their price objective on shares of Replimune Group from $18.00 to $19.00 and gave the company an "outperform" rating in a report on Wednesday, February 4th. Piper Sandler boosted their price objective on shares of Replimune Group from $13.00 to $14.00 and gave the company an "overweight" rating in a report on Thursday, February 5th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Replimune Group in a report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Replimune Group currently has a consensus rating of "Hold" and a consensus price target of $10.00.
Check Out Our Latest Stock Analysis on REPL
Replimune Group Company Profile
(
Get Free Report)
Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.
Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
